Home/Filings/4/0001140361-18-031328
4//SEC Filing

RAY DEBANJAN 4

Accession 0001140361-18-031328

CIK 0001501989other

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 6:51 PM ET

Size

8.3 KB

Accession

0001140361-18-031328

Insider Transaction Report

Form 4
Period: 2018-07-02
RAY DEBANJAN
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2018-07-02$22.56/sh3,000$67,6805,928 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-07-023,0002,710 total
    Exercise: $1.26Exp: 2023-12-10Common Stock (3,000 underlying)
  • Exercise/Conversion

    Common Stock

    2018-07-02$1.26/sh+3,000$3,7808,928 total
Footnotes (2)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  • [F2]100% of the shares subject to the option are fully vested and exercisable.

Documents

1 file

Issuer

CytomX Therapeutics, Inc.

CIK 0001501989

Entity typeother

Related Parties

1
  • filerCIK 0001706863

Filing Metadata

Form type
4
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 6:51 PM ET
Size
8.3 KB